Please assess the completion status of the following clinical trial:

Trial Title: Serologically Active, Clinically Stable Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets ACR criteria for SLE~* Inactive or stable in lupus activity~* History of positive dsDNA~* Current prednisone dose no more than 15 mg daily~Exclusion Criteria:~* Active infections~* Poorly controlled diabetes mellitus~* Pregnancy~* Uncontrolled hypertension

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone arm (Type: ACTIVE_COMPARATOR): Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
- Placebo (Type: PLACEBO_COMPARATOR): Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).